SAB Biotherapeutics: Funding, Investors & Team (Oct 2026)
Targeted, totally human polyclonal antibodies for C diff, seasonal influenza, and Type 1 diabetes are being developed to advance a new class of immunotherapies without the use of human donors.
SAB Biotherapeutics has raised $223M across 3 funding rounds on record, the most recent an undisclosed round of $85.0M announced in Mar 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SAB Biotherapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
SAB Biotherapeutics Funding Rounds
SAB Biotherapeutics raised $8.0M in an undisclosed round announced in Jan 2023.
9 months later, an undisclosed round of $130M was announced in Oct 2023.
2.4 years later, an undisclosed round of $85.0M was announced in Mar 2026.
SAB Biotherapeutics Founders and Leadership Team
Contact details for the SAB Biotherapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →SAB Biotherapeutics Funding Compared to Other Biotechnology Startups
SAB Biotherapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SAB Biotherapeutics in Biotechnology and Sioux Falls
Companies Similar to SAB Biotherapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
SAB Biotherapeutics Funding FAQs
What does SAB Biotherapeutics do?
Targeted, totally human polyclonal antibodies for C diff, seasonal influenza, and Type 1 diabetes are being developed to advance a new class of immunotherapies without the use of human donors.
How much funding has SAB Biotherapeutics raised?
SAB Biotherapeutics has raised $223M across 3 rounds on record. The most recent is an undisclosed round of $85.0M announced in Mar 2026.
When did SAB Biotherapeutics last raise funding?
SAB Biotherapeutics' most recent funding round on record is an undisclosed round of $85.0M, announced in Mar 2026.
Who founded SAB Biotherapeutics?
FundedIQ lists Eddie J Sullivan (Founder) at SAB Biotherapeutics.
Who is the CEO of SAB Biotherapeutics?
Eddie Sullivan is listed as CEO at SAB Biotherapeutics.
Where is SAB Biotherapeutics headquartered?
SAB Biotherapeutics is based in Sioux Falls, South Dakota, United States.
How many employees does SAB Biotherapeutics have?
SAB Biotherapeutics is in the 51-100 employee band.
How does SAB Biotherapeutics' funding compare to other Biotechnology startups?
SAB Biotherapeutics' latest round of $85.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's SAB Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SAB Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.